HK1017350A1 - Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action - Google Patents

Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action

Info

Publication number
HK1017350A1
HK1017350A1 HK99102396A HK99102396A HK1017350A1 HK 1017350 A1 HK1017350 A1 HK 1017350A1 HK 99102396 A HK99102396 A HK 99102396A HK 99102396 A HK99102396 A HK 99102396A HK 1017350 A1 HK1017350 A1 HK 1017350A1
Authority
HK
Hong Kong
Prior art keywords
prodrugs
acylated
hydroxy methyl
immunomodulator
action
Prior art date
Application number
HK99102396A
Other languages
English (en)
Inventor
Johannes Schneider
Werner Winter
Stephan Wnendt
Kai Zwingenberger
Kurt Eger
Michaela Akermann
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of HK1017350A1 publication Critical patent/HK1017350A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
HK99102396A 1996-04-09 1999-05-28 Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action HK1017350A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19613976A DE19613976C1 (de) 1996-04-09 1996-04-09 Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
PCT/EP1997/001475 WO1997037988A1 (de) 1996-04-09 1997-03-22 Acylierte n-hydroxymethyl thalidomid-prodrugs mit immunomodulatorischer wirkung

Publications (1)

Publication Number Publication Date
HK1017350A1 true HK1017350A1 (en) 1999-11-19

Family

ID=7790778

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99102396A HK1017350A1 (en) 1996-04-09 1999-05-28 Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action

Country Status (13)

Country Link
US (1) US6417197B1 (xx)
EP (1) EP0892794B1 (xx)
JP (1) JP2000508298A (xx)
CN (1) CN1102931C (xx)
AT (1) ATE212989T1 (xx)
AU (1) AU707144B2 (xx)
DE (2) DE19613976C1 (xx)
DK (1) DK0892794T3 (xx)
ES (1) ES2171923T3 (xx)
HK (1) HK1017350A1 (xx)
HU (1) HUP9902181A3 (xx)
PT (1) PT892794E (xx)
WO (1) WO1997037988A1 (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
WO1997045117A1 (en) * 1996-05-29 1997-12-04 Prototek, Inc. Prodrugs of thalidomide and methods for using same as modulators of t-cell function
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DE19743968C2 (de) * 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
PT1308444E (pt) * 1997-11-18 2006-08-31 Celgene Corp 2-( 2,6-dioxo-3-fluoropiperidina-3-il )- isoindolinas e a sua utilizacao para reduzir os niveis de tnf
US20010041716A1 (en) * 1999-12-02 2001-11-15 Laing Timothy J. Compositions and methods for locally treating inflammatory diseases
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
WO2002068414A2 (en) * 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
CN100488959C (zh) * 2003-03-27 2009-05-20 天津和美生物技术有限公司 水溶性的酞胺哌啶酮衍生物
WO2005016326A2 (en) * 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
CN100398534C (zh) * 2003-09-15 2008-07-02 天津和美生物技术有限公司 合成酞胺哌啶酮及其衍生物的方法
CA2538864C (en) * 2003-09-17 2013-05-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Thalidomide analogs as tnf-alpha modulators
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
PL1682126T3 (pl) * 2003-10-16 2009-12-31 Novartis Vaccines & Diagnostics Inc Podstawione benzazole i ich zastosowanie jako inhibitorów kinazy Raf
ITMI20041113A1 (it) * 2004-06-01 2004-09-01 Antibioticos Spa Processo per la sintesi della talidomide
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
EP2004614B1 (en) 2006-04-13 2016-10-19 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Tetrahalogenated compounds useful as inhibitors of angiogenesis
PT2358697E (pt) * 2008-10-29 2016-02-03 Celgene Corp Compostos de isoindolina para utilização no tratamento do cancro
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
TWI782395B (zh) * 2016-01-08 2022-11-01 美商西建公司 抗增生化合物，及其醫藥組合物及用途
US20200199097A1 (en) * 2017-08-21 2020-06-25 Nanjing Noratech Pharmaceuticals Co., Ltd Pomalidomide derivative and preparation method therefor
CN111499610A (zh) * 2019-01-31 2020-08-07 南京诺瑞特医药科技有限公司 泊马度胺前体药物盐的多晶型物
EP3771711A1 (en) 2019-07-29 2021-02-03 Bayer Animal Health GmbH Pyrazole derivatives for controlling arthropods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
JP3204972B2 (ja) * 1991-04-17 2001-09-04 グリューネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 新規サリドマイド誘導体、その製造方法並びにこれを薬剤として使用する方法
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Also Published As

Publication number Publication date
PT892794E (pt) 2002-07-31
EP0892794B1 (de) 2002-02-06
US6417197B1 (en) 2002-07-09
DE59706313D1 (de) 2002-03-21
DE19613976C1 (de) 1997-11-20
HUP9902181A2 (hu) 2000-04-28
JP2000508298A (ja) 2000-07-04
AU707144B2 (en) 1999-07-01
DK0892794T3 (da) 2002-04-15
WO1997037988A1 (de) 1997-10-16
EP0892794A1 (de) 1999-01-27
CN1215397A (zh) 1999-04-28
AU2505297A (en) 1997-10-29
HUP9902181A3 (en) 2002-11-28
ES2171923T3 (es) 2002-09-16
ATE212989T1 (de) 2002-02-15
CN1102931C (zh) 2003-03-12

Similar Documents

Publication Publication Date Title
HK1017350A1 (en) Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
HU78083A (hu) Mátrix metalloproteáz inhibitor hatású helyettesített 4-diaril-vajsav és 5-diaril-pentánsav-származékok, előállításuk és a vegyületeket tartalmazó gyógyászati készítmények
NO159017C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,2,3,4-tetrahydroisokinolin-3-karboksylsyre-derivater.
MY102866A (en) Amide derivatives.
EP0691333A3 (xx)
MXPA03000547A (es) Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares.
FR2707089B1 (fr) Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
HUP9800964A2 (hu) O- és S-tartalmú 6 tagú benzo-kondenzált heterociklusos vegyületek, eljárás ezek előállítására, és ezeket tartalmazó gyógyászati készítmények
CA2251060A1 (en) Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
ATE47135T1 (de) Antikonvulsive mittel.
ATE92461T1 (de) Gegen die zerebrale insuffizienz wirksame verbindungen.
HUT62284A (en) Process for producing n-cycloalkylamine derivatives and pharmaceutical compositions comprising such compounds as active ingredient
HUP9903414A2 (en) 3-alkoxypyridine-2-carboxylic acid amide esters,their preparation and their use as drugs
IT1248068B (it) Derivati dell'eseridina ad attivita' anticolinesterasi, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100322